Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:50:28 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:GRCL from 2023-05-07 to 2024-05-06 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-02-22 08:45U:GRCLNews ReleaseGracell Biotechnologies Acquisition Completed
2024-02-20 07:45U:GRCLNews ReleaseGracell Biotechnologies Announces Shareholders ¢ € ™ Approval of Merger Agreement
2024-01-29 07:00U:GRCLNews ReleaseGracell Biotechnologies Announces FDA Clearance of IND Application ‚  for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment ‚  of Multiple Myeloma
2023-12-26 02:01U:GRCLNews ReleaseAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
2023-12-26 02:00U:GRCLNews ReleaseGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
2023-12-21 07:00U:GRCLNews ReleaseGracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
2023-12-11 19:30U:GRCLNews ReleaseGracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
2023-11-27 08:00U:GRCLNews ReleaseGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
2023-11-16 08:00U:GRCLNews ReleaseGracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
2023-11-13 07:30U:GRCLNews ReleaseGracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
2023-11-08 08:30U:GRCLNews ReleaseGracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
2023-11-02 09:00U:GRCLNews ReleaseGracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65 ¡ µ — Š ° American Society of Hematology Annual Meeting & Exposition
2023-11-01 16:00U:GRCLNews ReleaseGracell Biotechnologies to Participate in Four Upcoming Investor Conferences
2023-10-31 09:00U:GRCLNews ReleaseGracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART ¢ „ ¢ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
2023-10-30 08:30U:GRCLNews ReleaseGracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
2023-09-27 08:30U:GRCLNews ReleaseGracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
2023-09-26 16:01U:GRCLNews ReleaseGracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
2023-09-19 09:22U:GRCLNews ReleaseGracell Biotechnologies ¢ € ™ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
2023-09-14 09:15U:GRCLNews ReleaseGracell Biotechnologies to Participate in Three Upcoming Investor Conferences
2023-09-06 08:00U:GRCLNews ReleaseGracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
2023-08-24 16:10U:GRCLNews ReleaseGracell Biotechnologies to Participate in Two Upcoming Investor Conferences
2023-08-14 07:15U:GRCLNews ReleaseGracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
2023-08-07 11:14U:GRCLNews ReleaseGracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
2023-08-07 07:45U:GRCLNews ReleaseGracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
2023-07-31 16:02U:GRCLNews ReleaseGracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
2023-07-31 09:00U:GRCLNews ReleaseGracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
2023-06-20 08:30U:GRCLNews ReleaseGracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
2023-06-10 10:30U:GRCLNews ReleaseGracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin ¢ € ™s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
2023-06-03 14:15U:GRCLNews ReleaseGracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
2023-05-24 16:01U:GRCLNews ReleaseGracell Biotechnologies to Participate in Jefferies Healthcare Conference
2023-05-15 09:15U:GRCLNews ReleaseGracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
2023-05-15 07:00U:GRCLNews ReleaseGracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
2023-05-15 07:00U:GRCLNews ReleaseGracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
2023-05-11 17:28U:GRCLNews ReleaseGracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
2023-05-10 16:20U:GRCLNews ReleaseGracell Biotechnologies to Participate in Two Upcoming Investor Conferences